Department of Microbiology, Tumor, and Cell Biology, Karolinska Institutet, 171 77 Stockholm, Sweden.
Cell Metab. 2018 Jun 5;27(6):1163-1165. doi: 10.1016/j.cmet.2018.05.014.
Drugs that target angiogenesis are commonly used for treating various cancers, but their clinical benefits are limited. In a recent Science Translational Medicine article, Incio et al. (2018) provide mechanistic insight on the role of obesity in the development of anti-VEGF drug resistance in human patients and murine models of breast cancer.
针对血管生成的药物通常用于治疗各种癌症,但它们的临床疗效有限。在最近的《科学转化医学》杂志的一篇文章中,Incio 等人(2018)提供了肥胖在人类患者和乳腺癌小鼠模型中抗 VEGF 药物耐药性发展中的作用的机制见解。